×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BPTH – bio-path holdings, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BPTH
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/14
01:02 am
bpth
Bio-Path Holdings, Inc. (NASDAQ: BPTH) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Medium
Report
Bio-Path Holdings, Inc. (NASDAQ: BPTH) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
2/13
06:07 pm
bpth
Bio-Path Holdings Expands Global Patent Portfolio [Yahoo! Finance]
Low
Report
Bio-Path Holdings Expands Global Patent Portfolio [Yahoo! Finance]
2/13
04:01 pm
bpth
Bio-Path Holdings Expands Global Patent Portfolio
Medium
Report
Bio-Path Holdings Expands Global Patent Portfolio
2/13
09:40 am
bpth
Bio-Path Holdings Provides Key Clinical Updates [Yahoo! Finance]
Low
Report
Bio-Path Holdings Provides Key Clinical Updates [Yahoo! Finance]
2/13
08:00 am
bpth
Bio-Path Holdings Provides Key Clinical Updates
High
Report
Bio-Path Holdings Provides Key Clinical Updates
2/12
05:57 pm
bpth
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia [Yahoo! Finance]
High
Report
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia [Yahoo! Finance]
2/12
04:01 pm
bpth
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
High
Report
Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia
2/6
03:35 am
bpth
Bio-Path Holdings, Inc. (NASDAQ: BPTH) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Low
Report
Bio-Path Holdings, Inc. (NASDAQ: BPTH) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/14
05:27 pm
bpth
Form SCHEDULE 13G BIO-PATH HOLDINGS, INC. Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SCHEDULE 13G BIO-PATH HOLDINGS, INC. Filed by: ARMISTICE CAPITAL, LLC
2/12
10:59 am
bpth
Form S-1/A BIO-PATH HOLDINGS, INC.
Medium
Report
Form S-1/A BIO-PATH HOLDINGS, INC.
1/21
06:10 am
bpth
Form S-1 BIO-PATH HOLDINGS, INC.
Medium
Report
Form S-1 BIO-PATH HOLDINGS, INC.
1/10
04:15 pm
bpth
Form 8-K BIO-PATH HOLDINGS, INC. For: Jan 10
Low
Report
Form 8-K BIO-PATH HOLDINGS, INC. For: Jan 10
12/19
04:31 pm
bpth
Form 8-K BIO-PATH HOLDINGS, INC. For: Dec 19
Low
Report
Form 8-K BIO-PATH HOLDINGS, INC. For: Dec 19
12/13
05:16 pm
bpth
Form 8-K BIO-PATH HOLDINGS, INC. For: Dec 12
Medium
Report
Form 8-K BIO-PATH HOLDINGS, INC. For: Dec 12
12/12
04:16 pm
bpth
Form 8-K BIO-PATH HOLDINGS, INC. For: Dec 11
Low
Report
Form 8-K BIO-PATH HOLDINGS, INC. For: Dec 11
11/25
04:16 pm
bpth
Form 8-K BIO-PATH HOLDINGS, INC. For: Nov 19
Low
Report
Form 8-K BIO-PATH HOLDINGS, INC. For: Nov 19
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/16
Bio-Path Holdings Inc (NASDAQ: BPTH) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.
22.9%
4/13 Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting 12.4%
2/12 Form S-8 BIO-PATH HOLDINGS INC 7.7%
10/11 Bio-Path Holdings Inc (NASDAQ: BPTH) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 6.3%
2/3 Bio-Path Holdings Inc (NASDAQ: BPTH) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.1%
2/28 Bio-Path Holdings to Announce Fourth Quarter and Full Year 2019 Financial Results on March 6, 2020 4.4%
11/26 Form 8-K BIO-PATH HOLDINGS INC For: Nov 26 4.0%
11/15 Bio-Path Holdings, Inc (BPTH) CEO Peter Nielsen on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 2.4%
8/14 Q2/2019 6/30/2019 EPS -0.870 ZacksConsensus -0.600 ActVsEst (0.270) - Miss 1.8%
3/20 Form 4 BIO-PATH HOLDINGS INC For: Mar 18 Filed by: Nielsen Peter Henry 1.5%
4/13 Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting 12.4%
2/12 Form S-8 BIO-PATH HOLDINGS INC 7.7%
10/11 Bio-Path Holdings Inc (NASDAQ: BPTH) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 6.3%
2/3 Bio-Path Holdings Inc (NASDAQ: BPTH) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.1%
2/28 Bio-Path Holdings to Announce Fourth Quarter and Full Year 2019 Financial Results on March 6, 2020 4.4%
11/26 Form 8-K BIO-PATH HOLDINGS INC For: Nov 26 4.0%
11/15 Bio-Path Holdings, Inc (BPTH) CEO Peter Nielsen on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 2.4%
8/14 Q2/2019 6/30/2019 EPS -0.870 ZacksConsensus -0.600 ActVsEst (0.270) - Miss 1.8%
3/20 Form 4 BIO-PATH HOLDINGS INC For: Mar 18 Filed by: Nielsen Peter Henry 1.5%
TOP News Decliners
11/21
Form 8-K BIO-PATH HOLDINGS INC For: Nov 21
-35.1%
3/6 Bio-Path slips 4% on FY results [Seeking Alpha] -14.7%
3/9 Bio-Path Holdings Inc (NASDAQ: BPTH) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -12.3%
9/25 Form 8-K BIO-PATH HOLDINGS INC For: Sep 25 -11.3%
11/26 Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia -10.6%
12/4 Bio-Path Holdings Inc (NASDAQ: BPTH) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock. -9.7%
3/11 Bio-Path Holdings Appoints Ernst & Young as New Auditor -9.2%
1/8 Form 8-K BIO-PATH HOLDINGS INC For: Jan 08 -8.7%
9/24 Bio-Path Holdings Inc (NASDAQ: BPTH) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -7.9%
3/31 Form 4 BIO-PATH HOLDINGS INC For: Mar 27 Filed by: Molsbergen Tamaro Martina -7.8%
3/6 Bio-Path slips 4% on FY results [Seeking Alpha] -14.7%
3/9 Bio-Path Holdings Inc (NASDAQ: BPTH) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -12.3%
9/25 Form 8-K BIO-PATH HOLDINGS INC For: Sep 25 -11.3%
11/26 Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia -10.6%
12/4 Bio-Path Holdings Inc (NASDAQ: BPTH) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.00 price target on the stock. -9.7%
3/11 Bio-Path Holdings Appoints Ernst & Young as New Auditor -9.2%
1/8 Form 8-K BIO-PATH HOLDINGS INC For: Jan 08 -8.7%
9/24 Bio-Path Holdings Inc (NASDAQ: BPTH) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -7.9%
3/31 Form 4 BIO-PATH HOLDINGS INC For: Mar 27 Filed by: Molsbergen Tamaro Martina -7.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: